Addressing the achilles' heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation

Clinical Infectious Diseases

Volumn 59, Issue SUPPL.1, 2014, Pages

  Nachega, Jean B ^a,b,c   Uthman, Olalekan A ^d,e   Del Rio, Carlos ^f   Mugavero, Michael J ^g   Rees, Helen ^h   Mills, Edward J ^i,j  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^f EMORY UNIVERSITY   (United States)

^g University of Alabama at Birmingham   (United States)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

ART; HIV; test and treat; treatment as prevention; treatment cascade

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECENTRALIZATION; DRUG ABUSE; EARLY INTERVENTION; FOLLOW UP; HEALTH AUXILIARY; HEALTH CARE SYSTEM; HEALTH SERVICE; HIV TEST; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; INFECTION CONTROL; INFECTION PREVENTION; KENYA; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; MEN WHO HAVE SEX WITH MEN; PARAMEDICAL PERSONNEL; PATIENT EDUCATION; PATIENT MONITORING; POINT OF CARE TESTING; PREGNANT WOMAN; PRIORITY JOURNAL; PROSTITUTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESOURCE MANAGEMENT; SELF EVALUATION; SOUTH AFRICA; VIRUS TRANSMISSION; VULNERABLE POPULATION; HIV INFECTIONS; PATIENT CARE;

ANTI-HIV AGENTS; CONTINUITY OF PATIENT CARE; HIV INFECTIONS; HUMANS;

EID: 84904811666     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu299     Document Type: Article

References (59)

1. Cohen MS, Chen YQ, McCauleyM, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
2. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
3. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PloS One 2010; 5:e11068.
4. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-9.
5. Brown AE, Gill ON, Delpech VC. HIV treatment as prevention among men who have sex with men in the UK: is transmission controlled by universal access to HIV treatment and care? HIV Med 2013; 14:563-70.
6. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural Kwa-Zulu-Natal, South Africa. Science 2013; 339:966-71.
7. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793-800.
8. Delpech V, Brown A, Conti S, Polavarapu V, Yin Z. Reducing onward transmission: viral suppression among key population groups living with HIV in the United Kingdom [Abstract 018]. In: 19th Annual Conference of the British HIV Association, Manchester, UK, 2013.
9. Micek MA, Gimbel-Sherr K, Baptista AJ, et al. Loss to follow-up of adults in public HIV care systems in central Mozambique: identifying obstacles to treatment. J Acquir Immune Defic Synd 2009; 52:397-405.
10. Supervie V, Costagliola D. The spectrum of engagement in HIV care in France: strengths and gaps [Abstract #: 1030]. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013.
11. Wouters K, Fransen K, Beelaert G, et al. Use of rapid HIV test in low threshold center in Antwerp, Belgium, 2007-2012 [published online ahead of print 3 April 2014]. Int J STD AIDS 2014.
12. Mugglin C, Althoff KN, Wools-Kaloustian K, et al. Immunodeficiency at the start of ART: global view. In: 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2012.
13. European AIDS Clinical Society. European AIDS Clinical Society Guidelines version 7, 2013. Available at: http://www.eacsociety.org/Portals/0/Guidelines- Online-131014.pdf. Accessed 8 May 2014.
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendation on Integrase Inhibitor Use in Antiretroviral Treatment-Naive HIV-Infected Individuals from the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Department of Health and Human Services, 2013. Available at: http://aidsinfo.nih.gov/content files/lvguidelines/adultandadolescentgl.pdf. Accessed 8 May 2014.
15. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
16. World Health Organization. Antiretroviral Treatment Guidelines in HIV-infected Adults and Adolescents. Geneva, Switzerland: World Health Organization, 2013.
17. Department of STD, AIDS, and Viral Hepatitis. Saude: Ministerio da Saude. Available at: http://www.aids.gov.br/en/noticia/2013/franceadopts-new-national- policy-test-and-treat-hiv. Accessed 8 May 2014.
18. Wachira J, Kimaiyo S, Ndege S, Mamlin J, Braitstein P. What is the impact of home-based HIV counseling and testing on the clinical status of newly enrolled adults in a large HIV care program inWestern Kenya? Clin Inf Dis 2012; 54:275-81.
19. Lynch S, Ford N, van Cutsem G, et al. Public health. Getting HIV treatment to the most people. Science 2012; 337:298-300.
20. Fairall L, Bachmann MO, Lombard C, et al. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet 2012; 380:889-98.
21. Matovu F, Wabwire D, Nakibuuka J, Mubiru M, Bagenda D, Musoke P. Efficacy of using peer counselors and nurses to support adherence to HAART among HIV-1-infected patients at the prevention of MTCT program, Mulago Hospital, Kampala, Uganda: a randomized non-inferiority interventional trial. Paper 1016. In: 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011.
22. Sanne I, Orrell C, Fox MP, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet 2010; 376:33-40.
23. Thompson MA, Mugavero MJ, Amico KA, et al. Guidelines for improving entry into and retention in care for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012; 156: 817-33.
24. Lewin S, Munabi-Babigumira S, Glenton C, et al. Lay health workers in primary and community health care for maternal and child health and the management of infectious diseases. Cochrane Database Syst Rev 2010; 17:CD004015.
25. Duwell MM, Knowlton AR, Nachega JB, et al. Patient-nominated, community-based HIV treatment supporters: patient perspectives, feasibility, challenges, and factors for success in HIV-infected South African adults. AIDS Patient Care STDs 2013; 27:96-102.
26. Nachega JB, Chaisson RE, Goliath R, et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS 2010; 24:1273-80.
27. Nachega JB, Knowlton AR, Deluca A, et al. Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. A qualitative study. J Acquir Immune Defic Syndr 2006; 43(Suppl 1):S127-33. (Pubitemid 44885652)
28. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-90. (Pubitemid 44200639)
29. Vital signs: HIV prevention through care and treatment-United States. MMWR Morb Mortal Wkly Rep 2011; 60:1618-23.
30. Katz IT, Essien T, Marinda ET, et al. Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS 2011; 25:2177-81.
31. Adakun SA, Siedner MJ, Muzoora C, et al. Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda. J Acquir Immune Defic Syndr 2013; 62:317-21.
32. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223-31.
33. Lester RT, Mills EJ, Kariri A, et al. The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol. Trials 2009; 10:87.
34. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS 2011; 25:825-34.
35. Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and oncedaily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 2014; 58:1297-307.
36. ChungMH, Richardson BA, Tapia K, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med 2011; 8:e1000422.
37. Pradier C, Bentz L, Spire B, et al. Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials 2003; 4:121-31. (Pubitemid 36410916)
38. Mugavero MJ, Davila JA, Nevin CR, Giordano TP. From access to engagement: measuring retention in outpatient HIV clinical care. AIDS Patient Care STDs 2010; 24:607-13.
39. Institute of Medicine. Indicators Related to Continuous HIV Care and Access to Supportive Services. Monitoring HIV Care in the United States: Indicators and Data Systems. Washington, DC: The National Academies Press, 2012.
40. Gardner LI, Metsch LR, Anderson-Mahoney P, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS 2005; 19:423-31. (Pubitemid 40446189)
41. Bradford JB, Coleman S, Cunningham W. HIV System Navigation: an emerging model to improve HIV care access. AIDS Patient Care STDs 2007; 21(Suppl 1):S49-58.
42. HIV Prevention Trials Network (HPTN). HPTN 065 (TLC-Plus) Study Status. Available at: http://www.hptn.org/web%20documents/HPTN065/ WES065OverallUpdate26Jun12.pdf. Accessed 29 January 2014.
43. Volpp KG, Troxel AB, Pauly MV, et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med 2009; 360:699-709.
44. Volpp KG, John LK, Troxel AB, et al. Financial incentive-based approaches for weight loss: a randomized trial. JAMA 2008; 300:2631-7.
45. Stitzer ML, Polk T, Bowles S, Kosten T. Drug users' adherence to a 6-month vaccination protocol: effects of motivational incentives. Drug Alcohol Depend 2010; 107:76-9.
46. Seal KH, Kral AH, Lorvick J, et al. A randomized controlled trial of monetary incentives vs outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend 2003; 71:127-31. (Pubitemid 37289022)
47. Malotte CK, Hollingshead JR, Larro M. Incentives vs outreach workers for latent tuberculosis treatment in drug users. Am J Prev Med 2001; 20:103-7. (Pubitemid 32106944)
48. Haug NA, Sorensen JL. Contingency management interventions for HIV-related behaviors. Current HIV/AIDS Rep 2006; 3:154-9. (Pubitemid 44657373)
49. Rosen MI, Dieckhaus K, McMahon TJ, et al. Improved adherence with contingency management. AIDS Patient Care and STDS 2007; 21:30-40.
50. Kaplan R, Orrell C, Zwane E, Bekker LG, Wood R. Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS 2008; 22:1679-81.
51. Myer L, Zulliger R, Bekker LG, Abrams E. Systemic delays in the initiation of antiretroviral therapy during pregnancy do not improve outcomes of HIV-positive mothers: a cohort study. BMC Pregnancy Childbirth 2012; 12:94.
52. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS 2012; 26:2039-52.
53. Tenthani L, Haas AD, Tweya H, et al. Ministry of Health in Malawi and IeDEA Southern Africa. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ("Option B+") in Malawi. AIDS 2014; 28:589-98.
54. Imperial College London. PopART-reducing HIV transmission at a population level. Available at: http://www1.imperial.ac.uk/department ofmedicine/ divisions/infectiousdiseases/infectious-diseases/hiv-trials/hiv-prevention- technologies/popart/. Accessed 29 January 2014.
55. KwaZulu-Natal-Africa Centre. Treatment As Prevention (TasP) trial. Available at: http://www.africacentre.ac.za/NewsArchives/2010Archives/ FrenchAIDSResearchAgencyawardsAfricaCentre/tabid/439/Default. aspx. Accessed 29 January 2014.
56. Labome.Org. An HIV prevention program for Mochudi, Botswana. Available at: http://www.labome.org/grant/r01/ai/an/hiv/an-hivprevention-program-for- mochudi-botswana-7680502.html. Accessed 29 January 2014.
57. Barnighausen T, Bloom DE, Humair S. Economics of antiretroviral treatment vs. circumcision for HIV prevention. Proc Natl Acad Sci USA 2012; 109:21271-6.
58. Granich R, Kahn JG, Bennett R, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PloS One 2012; 7:e30216.
59. Walensky RP, Ross EL, Kumarasamy N, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med 2013; 369:1715-25.